Geographic Arbitrage in European HealthTech: Why the Next Platform Deal Might Be in the Nordics, DACH or the Netherlands, Not London

Nelson Advisors
9 minutes ago
11 min read

Macro Capital Allocation and the Structural Decoupling of European HealthTech

The European healthcare technology (HealthTech) and medical technology (MedTech) landscape is undergoing a structural realignment. Between 2025 and 2030, the European HealthTech market is projected to expand from $96.68 Billion to $222.22 Billion, representing a compound annual growth rate (CAGR) of 18.11%. Concurrently, the European MedTech market maintains a valuation base of approximately €170 Billion with a positive net medical device trade balance of €5 Billion. Underneath these expanding macro figures lies a shift in institutional capital deployment: a structural transition from early-stage, speculative venture volume to cash-generative, late-stage private equity (PE) platform scale.

Capital deployment has concentrated into high-conviction platform assets. In the first half of 2025, transaction value across European healthcare and life sciences surged by 87% year-over-year to €31.8 Billion, even as overall deal count declined by 8%. This capital focus reflects how financial sponsors and strategic acquirers are bypassing unproven point solutions to acquire scaled, cash-generative platform targets. Sponsor buyout deployment expanded by 276% year-over-year to €29.6 billion, driven by record private equity dry powder reserves of €414 billion, private credit stabilization, and aggressive buy-and-build consolidation strategies.

Valuation benchmarks have decoupled based on earnings visibility, regulatory certification and defensible clinical utility. Enterprise value (EV) to revenue multiples across European HealthTech have normalised to a baseline band of 4.0x–6.0x, with a median of 4.8x. However, profitable software assets adhering to the "Rule of 40", where the sum of year-over-year revenue growth rate and EBITDA margin exceeds 40, command EV/EBITDA multiples between 10.0x and 14.0x, reaching up to 16.0x–22.0x for mission-critical Healthcare IT platforms. Premium AI-native clinical tools and interoperability infrastructure achieve enterprise valuations between 6.0x and 8.0x+ revenue. Conversely, unprofitable software entities lacking clear pathways to EBITDA expansion face valuation compression down to 3.0x–4.0x revenue.

This financial environment has laid the groundwork for geographic arbitrage across European mid-market private equity. While London historically commanded a disproportionate share of early-stage venture funding, institutional investors seeking scalable buy-and-build platform deals are increasingly looking to the DACH region (Germany, Austria, Switzerland), the Nordic countries and the Netherlands.

Sub-Sector Segment	EV / Revenue Multiple Band	EV / EBITDA Multiple Band	Primary Valuation Drivers & Capital Catalysts
AI-Native Clinical & Diagnostics	6.0x – 8.0x+	15.0x – 18.0x+	Proprietary algorithms, "Glass Box" model transparency, EU AI Act conformity
Data Interoperability Infrastructure	5.5x – 7.0x	12.0x – 15.0x	Net retention stability (>120%), Rule of 40 compliance, value-based care enablement
Healthcare IT (PE Operational Scale)	3.5x – 5.0x	16.0x – 22.0x	Recurring workflow SaaS, back-office automation, buy-and-build consolidation
MedTech Devices & Implants	2.5x – 4.5x	10.0x – 15.0x	Clinical trial clearance, gross margin defensibility, direct hospital procurement
Unprofitable Point Software Solutions	3.0x – 4.0x	Compressed / Non-Applicable	Lack of EBITDA conversion, single-hospital exposure, funding gap vulnerability

The London Trap: Capital Density v's Procurement & Scale Bottlenecks

London remains a premier center for early-stage capital formation in European technology, securing $409 million in venture and private equity capital during Q3 2025 alone and attracting $4.2 billion across UK healthcare technology in 2025. Supported by the UK government's NHS 10-Year Health Plan and shifting budget allocations, the UK serves as a launchpad for administrative AI and digital primary care tools. However, a structural disconnect exists between London's funding ecosystem and the operational reality of institutional scale within its primary domestic customer, the National Health Service (NHS).

The structural bottleneck stems directly from NHS commercial governance. Despite central guidance, commercial spending authority across England is fragmented across 42 Integrated Care Systems (ICSs) and their associated Integrated Care Boards (ICBs). Each local system maintains divergent commercial priorities, limited procurement capacity, and duplicated governance standards. HealthTech vendors attempting to scale across the NHS face complex, overlapping regulatory requirements, including the Public Contracts Regulations (PCR 2015), the Procurement Act 2023, the Provider Selection Regime, NHS Commercial standards, and Digital Technology Assessment Criteria (DTAC).

This structural fragmentation extends sales cycles for enterprise solutions from 6 months to over 24 months. Consequently, the UK market suffers from high pilot attrition, often termed the "Pilot Graveyard", where approximately 90% of AI and digital health solutions validated in clinical trials fail to transition from local pilots into system-wide, multi-year procurement contracts. Procurement decisions within the NHS remain largely driven by short-term upfront cost savings rather than long-term outcome measures or total cost of care reductions, neutralising the competitive advantage of high-margin software assets.

For private equity sponsors targeting platform buyouts, this market dynamic introduces operational friction. High entry valuations driven by London's venture capital density clash with extended sales cycles and constrained domestic scaling routes. UK HealthTech targets often carry inflated revenue multiples without matching EBITDA conversion. As sponsors prioritise cash generative stability, low customer churn and clear operational leverage, capital is shifting toward continental markets where structural integration, regulatory subsidies and recurring SaaS contracts offer predictable entry points.

The DACH Powerhouse: Regulatory Subsidies and Infrastructure Buy-and-Build

The DACH region (Germany, Austria, Switzerland) has established itself as an active market for private equity platform acquisitions. Characterised by high transaction volume, averaging approximately 160 healthcare M&A deals annually, DACH offers reasonable entry multiples, with target EBITDA multiples ranging from 6.0x to 13.0x and sales multiples spanning 1.2x to 2.9x for lower-to-mid market targets. This valuation environment contrasts with London's elevated software multiples, creating a foundation for buy-and-build value creation.

The primary operational catalyst across the German healthcare system is the Krankenhauszukunftsgesetz (KHZG). This federal legislative program allocated over €3 Billion in targeted hospital modernization and digitalization subsidies. Crucially, KHZG legally mandates capital expenditure across specific digital workflows, including digital discharge management systems (Entlassmanagement), automated clinical care coordination software, interoperable patient portals, cloud-based workflow automation, and cybersecurity hardening.

To enforce compliance, the German Federal Ministry of Health implemented the "DigitalRadar" evaluation instrument, which measures the digital maturity of hospitals across standardisation and data structure metrics. Hospitals that fail to meet mandated digital infrastructure benchmarks face financial penalties, converting software adoption from an elective operational decision into a statutory requirement.

This regulatory environment has accelerated sponsor backed buy and build consolidation across DACH hospital software and laboratory information systems (LIS). A key example of this trend was the public-to-private takeover of Nexus AG by global software investor TA Associates, alongside co-investor Luxempart. Nexus AG, a European vendor of modular Hospital Information Systems (HIS) and e-health workflow software, was taken private at an enterprise valuation reflecting a 19.3x TV/EBITDA multiple. The transaction generated returns for early backers, such as Luxempart's 1.4x multiple on invested capital (MoIC) and 14.2% IRR over a 2.5-year holding period, while facilitating a €48 Million co-investment to fund international add-on acquisitions and cloud transformation.

Similar consolidation strategies are visible across the DACH mid-market, as seen in private equity platforms involving software providers like Medavis, Frey, and ATOSS Software. ATOSS Software demonstrates the operational metrics sought by private equity buyers in DACH: generating €170.6 Million in annual revenue with an EBITDA margin of 39.8%, supported by recurring software subscription and maintenance revenues accounting for over 65% of software turnover. The combination of statutory digital funding mandates, sticky on-premise to SaaS migrations, and fragmented regional competitors positions DACH as a resilient engine for European health IT platform roll-ups.

The Nordic Incubator: High Digital Penetration and Scalable NRR Metrics

The Nordic region (Sweden, Denmark, Finland, Norway) represents a mature, digitally integrated healthcare market in Europe. Despite representing just 3% of the total European population, the Nordics attracted €6.7 billion in venture and growth capital in 2025—accounting for 16% of all European private capital deployment. This performance is sustained by high national digital literacy, centralised health data registries, unified personal identity infrastructure, and single-payer healthcare models open to public-private technology partnerships.

For financial sponsors, the Nordics serve as an incubator for clinical platforms, remote patient monitoring (RPM), oncology diagnostics, and digital social care. The Swedish home healthcare technology market alone is projected to reach $8.1 Billion by 2030, growing at a 10.3% CAGR. The unified infrastructure of Nordic health systems allows HealthTech companies to achieve market penetration, commercial validation, and clear unit economics faster than in fragmented markets.

These structural conditions translate directly into defensible financial metrics for mid-market software vendors. Nordic HealthTech platforms regularly achieve Net Revenue Retention (NRR) rates exceeding 120%, sustained by deep product integration into regional health authorities and municipal social care systems. High switching costs associated with municipal IT integrations keep annual customer churn below 5%, while gross margins reach 75% to 85%, allowing incremental contract expansions to flow directly into EBITDA cash generation.

Private equity consolidators utilise Nordic targets as product engines within cross-border buy-and-build structures. For example, Dutch private equity firm Main Capital Partners acquired Finnish digital health platform VideoVisit, rebranded the entity as Oiva Health, and executed a buy-and-build strategy to consolidate the virtual care and digital social care market across Finland and Denmark. By combining Nordic software design and validated clinical platforms with broad pan-European distribution vehicles, private equity sponsors systematically scale Nordic assets into broader European category leaders.

The Dutch Playbook: Specialised PE Platforms and Programmatic Roll-Up Mechanics

The Netherlands has established itself as an operational command center for mid-market private equity roll-ups in European software and HealthTech. Benelux-focused and pan-European financial sponsors headquartered in the Netherlands—most notably Main Capital Partners and Waterland Private Equity—have refined a programmatic approach to healthcare software consolidation.

Main Capital Partners demonstrates this operational strategy by building specialized software groups in high-barrier healthcare sub-sectors. Main's strategy focuses on identifying lower-middle market platform targets earning between €5 million and €50 million in revenue and systematically executing bolt-on acquisitions to construct broad product suites.

Main's execution in the healthcare space includes SDB Groep, where Main acquired a core healthcare HR and payroll software vendor and executed targeted add-on acquisitions across disability care planning, childcare management, and healthcare e-learning modules to construct a unified social care SaaS platform. Similarly, Main built Enovation into a regional health communication platform focused on secure clinical messaging, patient data transfer, and care network interoperability. In the hospital workflow segment, Main acquired IQ Messenger, a Netherlands-based vendor-neutral critical alarm management platform, and launched a pan-European buy-and-build expansion across DACH, France, and the Nordics.

Waterland Private Equity applies a complementary programmatic buy-and-build methodology. Having completed over 1,100 total acquisitions—including 160 platform investments and 950 add-on deals—Waterland targets fragmented sectors shaped by structural demographic trends, such as aging populations and digital healthcare transformation. Waterland utilises specialised fund vehicles, including Article 8 sustainability-focused funds and dedicated continuation funds, allowing them to hold high-performing platforms over extended operational horizons to compound value through add-on acquisitions.

To maintain expansion momentum without forcing premature exits, European software consolidators increasingly deploy dedicated continuation vehicles. Main Capital’s €520 Million continuation fund illustrates this structural shift, enabling sponsors to retain ownership of mature, high-margin platforms like SDB Groep while providing liquidity to early limited partners (LPs). This permanent-capital orientation aligns with the multi-year implementation cycles and deep regulatory integrations inherent to healthcare enterprise software.

Regional Market	Primary HealthTech & Software Specialisation	Average Entry EV / EBITDA	Key Regulatory & Operational Catalysts	Strategic Value-Creation Mechanics
London / UK	Administrative AI, Digital Primary Care, Triage	Elevated / Growth-Weighted (14.0x–20.0x+)	NHS 10-Year Plan, central R&D grants	Venture-to-venture scale, global expansion launchpad
DACH Region	Hospital Information Systems (HIS), LIS, WFM	Compressed / Value-Weighted (6.0x–13.0x)	Krankenhauszukunftsgesetz(KHZG), DigitalRadar	Public-to-private LBOs, KHZG subsidy modernization
Nordic Region	Remote Patient Monitoring, AI Diagnostics, Home Care	Mid-Tier Defensible (10.0x–14.0x)	High national digitization, centralized identity	High NRR (>120%), international expansion roll-ups
Netherlands	Interoperability, Social Care SaaS, Critical Messaging	Platform Multiples (10.0x–15.0x)	Unified regional care networks, standardized APIs	Programmatic M&A, continuation fund compounding

Strategic Mechanics of Geographic Arbitrage: Building the Pan-European Platform

The economic rationale for geographic arbitrage in European HealthTech rests on fundamental valuation and operational discrepancies across national borders. By leveraging variations in entry multiples, market maturity, and regulatory structures, private equity sponsors can systematically generate operational alpha through programmatic consolidation.

Arbitrage begins at the entry stage, where unconsolidated lower-middle market targets across Continental Europe, defined as businesses generating €5 Million to €50 Million in annual revenue with operating EBITDA between €1 Million and €10 Million, trade at reasonable valuations.

In the DACH MedTech and HealthTech sectors, target EBITDA multiples trade in the 6.0x to 13.0x range, with sales multiples between 1.2x and 2.9x. These entry figures contrast with early-stage software valuations in London, allowing sponsors to acquire localized market leaders with proven profitability without paying speculative growth premiums.

Once a platform asset is acquired, value creation shifts to cross-border operational integration. Sponsors combine specialised regional strengths: layering Nordic clinical software and remote monitoring capabilities onto robust DACH Hospital Information System (HIS) back-office infrastructure, while utilising Dutch communication middleware (such as IQ Messenger or Enovation) to ensure data flow across hospital departments. By enforcing Rule of 40 operational discipline, standardizing SaaS contract structures, and automating back-office processes, sponsors systematically expand operating EBITDA margins from historical 10%–15% levels toward 30%–40%.

The financial engine of geographic arbitrage culminates in multiple expansion at exit. While individual regional targets are acquired at lower-middle market multiples (6.0x–13.0x EBITDA), the resulting aggregated pan-European platform commands a premium valuation. Multi-country platform assets generating substantial recurring EBITDA and demonstrating regulatory compliance across the EU are highly strategic. These scaled platforms command exit multiples of 16.0x to 22.0x EBITDA (or 6.0x to 8.0x+ EV/Revenue) when sold to global strategic acquirers, such as Thermo Fisher Scientific, Deutsche Börse, CompuGroup Medical, or Dedalus, or secondary private equity buyers seeking de-risked assets.

Sponsor Firm	Core Healthcare Platforms	Target Geographic Footprint	Primary Buy-and-Build Strategy
Main Capital Partners	SDB Groep, Enovation, Oiva Health, IQ Messenger	Benelux, DACH, Nordics	Social care SaaS, workflow automation, critical interoperability messaging
Waterland Private Equity	Athera, Keylane, Partou (Article 8 Fund)	Benelux, DACH, UK, Nordics	Outpatient clinic roll-ups, specialized care software, demographic expansion
TA Associates	Nexus AG (co-invested by Luxempart)	DACH, Broad Europe	Enterprise Hospital Information Systems (HIS) take-privates, cloud transition

Strategic Outlook and Recommendations for Private Equity Dealmakers

As the European HealthTech sector completes its transition into a disciplined, value-driven market, capital allocation strategies must align with geopolitical and regulatory realities. The strategic center of gravity for platform M&A has shifted toward Western Continental Europe, where statutory funding mandates, sticky customer relationships, and reasonable entry multiples support leveraged buyout models.

Investment committees evaluating UK-based targets should underwrite growth models assuming conservative domestic NHS expansion timelines unless the asset holds established ICB enterprise framework contracts. UK acquisitions should be evaluated primarily as product engines or technological bolt-ons for international distribution platforms, mitigating exposure to prolonged domestic procurement cycles and pilot-stage attrition.

Deal teams should capitalise on DACH regulatory mandates by targeting lower-middle market healthcare software providers in Germany, Austria, and Switzerland that directly serve KHZG-funded categories—specifically digital discharge planning, clinical care coordination, and interoperability portals. Acquirers must verify target alignment with DigitalRadar maturity metrics to ensure recurring revenue streams are insulated by statutory compliance penalties.

When targeting Nordic assets, acquirers should leverage high Net Revenue Retention (>120%) and clinically validated AI capabilities. Value creation strategies must prioritise immediate commercial expansion into DACH and Benelux distribution channels, pairing Nordic software innovation with larger continental hospital end-markets.

Finally, financial sponsors should execute programmatic Dutch style buy and build mechanics. By establishing platform holding companies in Benelux or DACH, sponsors can acquire complementary niche vendors at single digit EBITDA multiples, implement standardised operating playbooks, and compound earnings within dedicated platform vehicles. Maintaining strict Rule of 40 underwriting discipline will ensure capital remains concentrated in cash-generative, defensible platforms built to capture premium exits across the European landscape.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #MedTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech #ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada #Commonwealth #CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics